A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation. This clinical evidence is reshaping the conversation around proton therapy, a treatment that uses protons instead of photons to deliver radiation with greater precision, reducing collateral damage to healthy tissue. The study, led by the University of Texas MD Anderson Cancer Center, enrolled 440 patients across 21 proton centers in the U.S. and tracked outcomes over several years. The results are expected to accelerate investment in proton therapy infrastructure, including a new proton center scheduled to open this summer in Boca Raton, Florida.
Proton therapy’s ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage that has long been hypothesized but now has stronger data to support it. The core limitation of traditional photon radiation is that beams pass through the body, leaving an exit dose that can damage healthy tissues. This collateral exposure has been a concern for oncologists, particularly for patients with longer life expectancies who are at risk for secondary cancers or other radiation-induced complications. The new trial provides some of the clearest evidence yet that proton therapy can mitigate these risks while improving survival outcomes.
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) anticipated this shift. In November 2025, the company acquired Liora Technologies Europe Ltd., now a subsidiary of LIXTE, which developed the electronically controlled LiGHT proton therapy platform. This acquisition positions LIXTE at the forefront of the proton therapy market, which is expected to grow as more facilities adopt the technology. The LiGHT platform offers advantages in precision and cost-effectiveness, potentially making proton therapy more accessible. LIXTE’s strategic move aligns with the growing body of evidence supporting proton therapy’s clinical benefits.
The implications of this announcement extend beyond individual patient outcomes. The survival gap demonstrated in the trial—a 9.9 percentage point difference in five-year overall survival—is likely to influence treatment guidelines and insurance coverage decisions. As more data emerges, proton therapy may become the standard of care for certain cancers, driving demand for new facilities and technology. The new proton center in Boca Raton is just one example of the infrastructure investments being made in response to these findings.
For investors, LIXTE’s early move into proton therapy through the Liora acquisition could prove prescient. The company’s forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, highlight risks and uncertainties, but the clinical data provides a strong tailwind. As the healthcare community digests the implications of this landmark trial, the conversation around cancer treatment is changing, and LIXTE is positioned to be part of that change.
